Business1 outlet
Shionogi-Backed Apnimed Seeks $160 Million US IPO
Apnimed Inc., a clinical-stage biopharmaceutical company backed by Shionogi, is planning to go public on US markets with an IPO targeting up to $160 million in capital raises. The company specializes in developing late-stage treatments for sleep apnea, a significant sleep disorder affecting millions of patients worldwide.
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
How does this lean?
Comments
0No comments yet. Say what you noticed in the coverage.
Trending